Can you take NAD+ / NMN / NR and Resveratrol together?

Read Off Label doesn't make stack recommendations — see the disclaimer. Both compounds have individual mechanism, dose, and risk profiles documented on their respective pages; combining them is a clinical question that depends on the goal, indication, and other context.

Rankings / Comparisons

NAD+ / NMN / NR vs Resveratrol

The classic NAD+ vs sirtuin-activator debate — different pathways aimed at the same aging hallmark.

Reviewed by Read Off Label · How we grade

Bottom line

On the composite score, NAD+ / NMN / NR (B+, 7.1/10) edges out Resveratrol (B-, 6.2/10) — but the right pick depends on the specific outcome you're optimising for.

NAD+ / NMN / NR

B+ 7.1/10

aka Nicotinamide mononucleotide, Nicotinamide riboside, Niagen

Evidence: Moderate (raises NAD+ reliably); Weak (functional/outcome endpoints) (6/10)
Benefit: Varies (5/10)
Risk: Low (9/10 safety)
Legality: OTC
Dose: 250-1000 mg/day NMN or NR (sublingual or oral); IV NAD+ infusions also used
Class: Supplement
Last reviewed: Jun 8, 2026

Read Off Label grades NAD+ / NMN / NR as B+ (7.1/10) based on moderate evidence, variable benefit magnitude, and a low-risk safety profile.

Yoshino 2021: NMN 250 mg/day improved muscle insulin sensitivity 25% in prediabetic women.

Typical use: 250-1000 mg/day NMN or NR (sublingual or oral); IV NAD+ infusions also used — OTC.

What it is

Yoshino 2021: NMN 250 mg/day improved muscle insulin sensitivity 25% in prediabetic women. Multiple RCTs show elevated NAD+ but inconsistent functional outcomes (strength, cognition, CV markers). Boosting NAD+ is easy; demonstrating clinical benefit is not.

Mechanism

Precursors to NAD+ — essential cofactor for sirtuins (SIRT1-7), PARPs, CD38; ETC; cellular NAD+ declines with age

Full NAD+ / NMN / NR review →

Resveratrol

B- 6.2/10

Evidence: Weak-Moderate (4.5/10)
Benefit: Low-Med (3.5/10)
Risk: Low (9/10 safety)
Legality: OTC
Dose: 150-500 mg/day trans-resveratrol; ideally micronized or with fat for absorption
Class: Supplement
Last reviewed: Jun 8, 2026

Read Off Label grades Resveratrol as B- (6.2/10) based on weak-moderate evidence, low-med benefit magnitude, and a low-risk safety profile.

Oft-cited as foundational longevity compound but human RCTs largely unimpressive.

Typical use: 150-500 mg/day trans-resveratrol; ideally micronized or with fat for absorption — OTC.

What it is

Oft-cited as foundational longevity compound but human RCTs largely unimpressive. Poor bioavailability (~1%). Metabolites may be active. 2025 meta-analysis: no significant SIRT1 effect in humans. Popularity persists despite modest signals.

Mechanism

Trans-resveratrol proposed SIRT1 activator (debated — likely indirect); AMPK activation; anti-inflammatory; vascular endothelial effects; poor oral bioavailability

Full Resveratrol review →

Common questions

Which is better, NAD+ / NMN / NR or Resveratrol?: On the composite score, NAD+ / NMN / NR (B+, 7.1/10) edges out Resveratrol (B-, 6.2/10) — but the right pick depends on the specific outcome you're optimising for.
What's the difference between NAD+ / NMN / NR and Resveratrol?: The classic NAD+ vs sirtuin-activator debate — different pathways aimed at the same aging hallmark.
Can you take NAD+ / NMN / NR and Resveratrol together?: Read Off Label doesn't make stack recommendations — see the disclaimer. Both compounds have individual mechanism, dose, and risk profiles documented on their respective pages; combining them is a clinical question that depends on the goal, indication, and other context.

This is an independent synthesis of published research by a non-clinician. Comparison-page verdicts use the composite Read Off Label score as a tiebreaker, but the right pick for any given person depends on indication, context, and clinician input. See the full disclaimer and methodology.